Durata Therapeutics Inc  

(Public, NASDAQ:DRTX)   Watch this stock  
Find more results for DRTX
12.67
-0.11 (-0.86%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.58 - 13.09
52 week 6.65 - 16.99
Open 12.79
Vol / Avg. 182,767.00/523,414.00
Mkt cap 337.53M
P/E     -
Div/yield     -
EPS -2.64
Shares 26.64M
Beta     -
Inst. own 92%
May 21, 2014
Durata Therapeutics Inc Annual Meeting of Stockholders - 11:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 Durata Therapeutics Inc Earnings Release (Estimated) Add to calendar
Mar 14, 2014
Q4 2013 Durata Therapeutics Inc Earnings Release
Mar 14, 2014
Q4 2013 Durata Therapeutics Inc Earnings Conference Call
Mar 11, 2014
Durata Therapeutics Inc at ROTH Conference
Mar 11, 2014
Durata Therapeutics Inc at EBD BIO-Europe Spring
Feb 25, 2014
Durata Therapeutics Inc at RBC Capital Markets Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.21% -66.57%
Return on average equity -136.37% -150.73%
Employees 68 -
CDP Score - -

Address

Suite 2550, 200 South Wacker Drive
CHICAGO, IL 60606
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Officers and directors

Richard U. De Schutter Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Paul R. Edick Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Corey N. Fishman Chief Financial Officer, Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Michael W. Dunne M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
John Shannon Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 70
Bio & Compensation  - Reuters
Brenton K. Ahrens Independent Director
Age: 47
Bio & Compensation  - Reuters
Lisa M. Giles Independent Director
Age: 54
Bio & Compensation  - Reuters
Ronald M. Hunt Independent Director
Age: 48
Bio & Compensation  - Reuters
Kevin C. O'Boyle CPA Independent Director
Age: 58
Bio & Compensation  - Reuters